New and Emerging Medical Therapies in Parkinson's Disease.
Identifieur interne : 000005 ( Main/Exploration ); précédent : 000004; suivant : 000006New and Emerging Medical Therapies in Parkinson's Disease.
Auteurs : Mitesh Lotia [États-Unis] ; Joseph Jankovic [États-Unis]Source :
- Expert opinion on pharmacotherapy ; 2016.
Abstract
Parkinson's disease (PD) is one of the most challenging neurodegenerative disorders to treat as it manifests with a large variety of troublesome, and often disabling, motor and non-motor symptoms. Despite limitations, such as motor and other complications, levodopa remains the most effective drug in the treatment of PD. Areas covered: In this review, we focus on phase 2 and 3 studies describing new and emerging medical therapies in PD. We discuss new formulations of levodopa, medications that prolong levodopa response and ameliorate levodopa-induced dyskinesias, and innovative delivery methods that are currently being evaluated in clinical trials or are in development with the promise of better efficacy and tolerability. We also describe novel non-dopaminergic drugs that have been identified for treatment of motor and non-motor symptoms. A specific section is designated for potential disease modifying therapies. Expert Opinion: Alternative formulations of levodopa appear to be promising especially to help with the motor fluctuations either by providing sustained benefits with controlled released formulations or ameliorate sudden OFF by formulations such as inhaled levodopa. Several different medications affecting non-dopaminergic pathways are being evaluated which may aide levodopa. As the understanding of the disease grows further, numerous novel neuroprotective or disease modifying therapies have been suggested. This along with development of medications to treat various non-motor symptoms will help improve quality of life of patients with PD.
DOI: 10.1517/14656566.2016.1149163
PubMed: 26830844
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000000
- to stream PubMed, to step Curation: 000000
- to stream PubMed, to step Checkpoint: 000002
- to stream Ncbi, to step Merge: 000536
- to stream Ncbi, to step Curation: 000536
- to stream Ncbi, to step Checkpoint: 000536
- to stream Main, to step Merge: 000005
- to stream Main, to step Curation: 000005
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">New and Emerging Medical Therapies in Parkinson's Disease.</title><author><name sortKey="Lotia, Mitesh" sort="Lotia, Mitesh" uniqKey="Lotia M" first="Mitesh" last="Lotia">Mitesh Lotia</name><affiliation wicri:level="1"><nlm:affiliation>a Fellow, Movement disorders, Parkinson's Disease Center and Movement Disorders Clinic , Department of Neurology Baylor College of Medicine , 7200 Cambridge St, Suite 9A, Houston , TX 77030-4202 , Tel: 713-798-9014 , Fax: 713-798-6808 , Email: mitesh.lotia@bcm.edu.</nlm:affiliation><country wicri:rule="url">États-Unis</country><wicri:regionArea>a Fellow, Movement disorders, Parkinson's Disease Center and Movement Disorders Clinic , Department of Neurology Baylor College of Medicine , 7200 Cambridge St, Suite 9A, Houston , TX 77030-4202 , Tel: 713-798-9014 , Fax: 713-798-6808 </wicri:regionArea><wicri:noRegion>Fax: 713-798-6808 </wicri:noRegion></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="doi">10.1517/14656566.2016.1149163</idno><idno type="RBID">pubmed:26830844</idno><idno type="pmid">26830844</idno><idno type="wicri:Area/PubMed/Corpus">000000</idno><idno type="wicri:Area/PubMed/Curation">000000</idno><idno type="wicri:Area/PubMed/Checkpoint">000002</idno><idno type="wicri:Area/Ncbi/Merge">000536</idno><idno type="wicri:Area/Ncbi/Curation">000536</idno><idno type="wicri:Area/Ncbi/Checkpoint">000536</idno><idno type="wicri:Area/Main/Merge">000005</idno><idno type="wicri:Area/Main/Curation">000005</idno><idno type="wicri:Area/Main/Exploration">000005</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">New and Emerging Medical Therapies in Parkinson's Disease.</title><author><name sortKey="Lotia, Mitesh" sort="Lotia, Mitesh" uniqKey="Lotia M" first="Mitesh" last="Lotia">Mitesh Lotia</name><affiliation wicri:level="1"><nlm:affiliation>a Fellow, Movement disorders, Parkinson's Disease Center and Movement Disorders Clinic , Department of Neurology Baylor College of Medicine , 7200 Cambridge St, Suite 9A, Houston , TX 77030-4202 , Tel: 713-798-9014 , Fax: 713-798-6808 , Email: mitesh.lotia@bcm.edu.</nlm:affiliation><country wicri:rule="url">États-Unis</country><wicri:regionArea>a Fellow, Movement disorders, Parkinson's Disease Center and Movement Disorders Clinic , Department of Neurology Baylor College of Medicine , 7200 Cambridge St, Suite 9A, Houston , TX 77030-4202 , Tel: 713-798-9014 , Fax: 713-798-6808 </wicri:regionArea><wicri:noRegion>Fax: 713-798-6808 </wicri:noRegion></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></analytic><series><title level="j">Expert opinion on pharmacotherapy</title><idno type="e-ISSN">1744-7666</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is one of the most challenging neurodegenerative disorders to treat as it manifests with a large variety of troublesome, and often disabling, motor and non-motor symptoms. Despite limitations, such as motor and other complications, levodopa remains the most effective drug in the treatment of PD. Areas covered: In this review, we focus on phase 2 and 3 studies describing new and emerging medical therapies in PD. We discuss new formulations of levodopa, medications that prolong levodopa response and ameliorate levodopa-induced dyskinesias, and innovative delivery methods that are currently being evaluated in clinical trials or are in development with the promise of better efficacy and tolerability. We also describe novel non-dopaminergic drugs that have been identified for treatment of motor and non-motor symptoms. A specific section is designated for potential disease modifying therapies. Expert Opinion: Alternative formulations of levodopa appear to be promising especially to help with the motor fluctuations either by providing sustained benefits with controlled released formulations or ameliorate sudden OFF by formulations such as inhaled levodopa. Several different medications affecting non-dopaminergic pathways are being evaluated which may aide levodopa. As the understanding of the disease grows further, numerous novel neuroprotective or disease modifying therapies have been suggested. This along with development of medications to treat various non-motor symptoms will help improve quality of life of patients with PD.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Texas</li></region><settlement><li>Houston</li></settlement><orgName><li>Baylor College of Medicine</li></orgName></list><tree><country name="États-Unis"><noRegion><name sortKey="Lotia, Mitesh" sort="Lotia, Mitesh" uniqKey="Lotia M" first="Mitesh" last="Lotia">Mitesh Lotia</name></noRegion><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000005 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000005 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26830844
|texte= New and Emerging Medical Therapies in Parkinson's Disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26830844" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a JankovicV1
| This area was generated with Dilib version V0.6.19. |  |